FDA Awards Enlivex’s GVHD Treatment Orphan Drug Status

Israeli company Enlivex, a part of Hadasit Bio-Holdings, has been awarded orphan drug status by the FDA for its product ApoCell. ApoCell is designed to treat Graft Versus Host Disease (GVHD), which affects up to 70 percent of heterologous bone marrow transplant recipients and can be lethal.